49 results about "Taurochenodeoxycholic acid" patented technology

The invention relates to new use of taurochenodeoxycholic acid, in particular to the new use of the taurochenodeoxycholic acid in prevention and treatment of osteoporosis. Through the study on taurochenodeoxycholic acid, the inventor found that the taurochenodeoxycholic acid can promote bone cells to secrete osteocalcin and improve lowered bone density. Thus, the taurochenodeoxycholic acid can beused in prevention or treatment of osteoporosis. After being administrated directly or being formed into various formulations, the taurochenodeoxycholic acid can be used for preventing or treating osteoporosis and other related diseases or states of osteoporosis.

The invention discloses a method of preparing tauroursodeoxycholic acid by biotransformation and application of the method. Biotransformation includes genetic codon optimization, engineered bacteria construction, engineered bacteria cultivation, substrate transformation and product preparation. Tauroursodeoxycholic acid is prepared by transforming a substrate through direct fermentation of engineered bacteria; the substrate is taurochenodeoxycholic acid. The substrate may reach 250 g/L in concentration; the reaction time is short; substrate transformation rate reaches 98% and above; the obtained product reaches 99% and above in purity; cyclic regeneration of NAD+ (nicotinamide adenine dinucleotide +) in the reaction system helps greatly reduce the usage of the coenzyme NAD+; the cost of enzymic catalytic reaction is reduced; industrial amplification is benefited. hydroxysteroid dehydrogenase and the regenerated coenzyme are connected via a flexible polypeptide sequence to form a protein fusion polymer; binding distances to the substrate and coenzyme are shorter; transformation progress is more facilitated; the number of fermenting times in industrial production is decreased; the process is simplified; time cost and material cost are saved.

The invention relates to hydroxysteroid dehydrogenase, and in particular to 7alpha-hydroxysteroid dehydrogenase (St-2-2) mutants. The amino acid sequences of the mutants are shown as SEQ ID NO:2, 3, 4, 5, 6, 7, 8, 9 or 10, and are obtained by changing the 255th amino acid of the 7alpha-hydroxysteroid dehydrogenase with an amino acid sequence of SEQ ID NO:1 from Ile to Tyr, Gln, Leu, Thr, Gly, Asn,Ser, Ala or Phe. In the presence of same substrates TCDCA and NADP<+>, enzyme activity of the mutants is respectively 1.49, 1.78, 1.79, 1.79, 1.93, 2.44, 2.58, 2.97 and 3.34 times of enzyme activityof a wild type hydroxysteroid dehydrogenase, and the mutant has a great application potential in a process of obtaining tauroursodeoxycholic acid (TUDCA) through biotransformation of taurochenodeoxycholic acid (TCDCA).

The invention relates to applications of serum taurochenodeoxycholic acid and chenodeocycholic acid as diagnostic markers in the preparation of medical instruments for diagnosing biliary atresia of newborns. The diagnostic markers of the medical instruments are content ratio of the taurochenodeoxycholic acid and the chenodeocycholic axid in serum. The invention also provides the application of chenodeocycholic acid. The application of diagnostic markers in biliary atresia of the newborns has the advantages that the application of the taurochenodeoxycholic acid and the chenodeocycholic acid as diagnostic markers of biliary atresia is proposed for the firstly time, so that the biliary atresia can be distinguished from other cholestasis diseases of newborns, the best operation time of children can be strived for, and therefore, the operation effect can be improved.

The invention relates to HSDH (hydroxysteroid dehydrogenase), in particular to a gene S1-a-1 of novel 7 alpha-HSDH. A nucleotide sequence of the gene is shown as SEQ ID NO.2, the novel 7 alpha-HSDH is encoded, a nucleotide sequence of the novel 7 alpha-HSDH is shown as SEQ ID NO.1, the novel 7 alpha-HSDH can be used for catalyzing CDCA (chenodeoxycholic acid) and TCDCA (taurochenodeoxycholic acid) to generate 7K-LCA (7-ketone lithocholic acid) and T7K-LCA (taurine-7-ketone lithocholic acid), wherein the catalytic activity of the novel 7 alpha-HSDH for CDCA is about 5 times of that of 7 alpha-HSDH of Sardinia clostridium, and the catalytic activity of the novel 7 alpha-HSDH for TCDCA is about over 2.5 times of that of 7 alpha-HSDH of Sardinia clostridium, therefore, the novel 7 alpha-HSDH has a great industrial application value.

The invention discloses a novel detection method of the tauroursodeoxycholic acid content and relevant substances. The relevant substances are taurochenodeoxycholic acid and ursodesoxycholic acid. The method includes the steps of preparing a reference substance solution and a reference substance test article solution, injecting the solutions into a liquid phase chromatographic instrument, recording the peak area of tauroursodeoxycholic acid in a chromatograph, calculating the HPLC content through anhydrous tauroursodeoxycholic acid according to an external standard method, preparing an impurity reference substance solution and a sample solution, injecting the solutions into the liquid phase chromatographic instrument, recording the peak areas of taurochenodeoxycholic acid and ursodesoxycholic acid in the chromatogram, and calculating the amounts of the relevant substances in the tauroursodeoxycholic acid sample according to the external standard method. By means of the method, an RID is applied through the efficient liquid phase chromatography. Under the same liquid phase spectrum conditions, two cholic acid substances, namely tauroursodeoxycholic acid and ursodesoxycholic acid which are large in polarity difference, can be effectively separated and accurately and quantitatively detected.

The invention provides a use of a combined serum metabolic marker in the preparation of a kit for diagnosing the progress of hepatopathy, the kit, and a method using the kit to screen serum metabolicmarkers, and relates to the technical field of serum metabolic markers. The combined serum metabolic marker is mainly composed of sodium glycochenodeoxycholate sulfate, glycochenodeoxycholic acid, glycodesoxycholic acid, glycocholic acid and taurochenodeoxycholic acid. The kit executes combined screening detection on the content of above serum metabolites in serum in order to realize assisted diagnosis of the progress of the hepatopathy of hepatopathy patients, so the difficult monitoring problem of the occurrence and development of the hepatopathy in existing clinic therapy of the hepatopathyis effectively alleviated.

The invention discloses a method for synthesizing tauroursodeoxycholic acid. The method comprises the steps that chenodeoxycholic acid is adopted as an initial raw material, reacting is carried out under the action of alkyl chloroformate to obtain mixed anhydride, then mixed anhydride and taurine react to obtain taurochenodeoxycholic acid, and taurochenodeoxycholic acid is sequentially subjected to an oxidation reaction and a hydrogenation reaction to obtain tauroursodeoxycholic acid. The method is low in cost, easy to operate, environmentally friendly and suitable for industrial production. Tauroursodeoxycholic acid prepared through the method is high in purity and yield.

The invention relates to hydroxysteroid dehydrogenase, in particular to a new 7alpha-hydroxysteroid dehydrogenase gene Y1-a-1. The nucleotide sequence of the gene is as shown in SEQ ID NO. 2. New 7alpha-hydroxysteroid dehydrogenase is coded, and the amino acid sequence of new 7alpha-hydroxysteroid dehydrogenase is as shown in SEQ ID NO.1; new 7alpha-hydroxysteroid dehydrogenase can catalyze chenodeoxycholic acid (CDCA) and taurochenodeoxycholic acid (TCDCA) to generate 7-ketone lithocholic acid (7K-LCA) and tauro 7-ketone lithocholic acid (T7K-LCA); the catalysis activity for CDCA or TCDCA is more than two times that of existing Sardinia clostridium 7alpha-HSDH, and the new 7alpha-hydroxysteroid dehydrogenase gene Y1-a-1 has an extremely large industrial application value.

The invention discloses a method for preparing tauro ursodesoxy cholic acid. The synthetic method comprises the following steps: a step (1) of adding ursodeoxycholic acid and phenolic compounds into chloralkane organic solvent at room temperature, performing cooling to 10-20 DEG C, adding a condensing agent; after the condensing agent is added dropwise, reacting completely at 5-45 DEG C, performing filtration and then concentrating filtrate to obtain a crude product, performing recrystallization and then obtaining high-finished product ursodesoxycholic acid phenolic ester as shown in a formula (II); a step (2) of adding the high-finished product ursodesoxycholic acid phenolic ester and taurine salt into an organic alcohol solvent to undergo the reaction completely, lowering the temperature to room temperature and then performing filtration, dissolving filter cake in water, using acid to adjust the pH to 1.0-3.0, and performing stirring and crystallization to obtain tauro ursodesoxy cholic acid as shown in a formula (I). The synthetic method is low cost, simple to operate, controllable and high in product yield and purity, an isomer impurity taurochenodeoxycholic acid of tauro ursodesoxy cholic acid can be controlled well, and the method is suitable for industrial production.

The invention discloses a tauroursodeoxycholic acid synthesis method. The method includes: taking poultry bile as a raw material, and performing process steps of dissolving, decontaminating, degreasing, deproteinizing, acidifying, treatment through ion-exchange resin and the like to obtain high-purity taurochenodeoxycholic acid; performing 7-hydroxyl selective oxidation of the taurochenodeoxycholic acid to obtain 3alpha-hydroxyl-7-keto-cholan-24-oyl-N-taurine; performing 7-keto selective reduction of 3alpha-hydroxyl-7-keto-cholan-24-oyl-N-taurine to obtain N-(3alpha,7beta-dihydroxy-5-beta-cholan-24-oyl)-taurine; finally performing re-crystallization and purification to obtain high-purity tauroursodeoxycholic acid. Cheap raw materials are adopted for acquisition of high-additional-value tauroursodeoxycholic acid through two-step reaction, short chemical synthesis route, high yield, high target product purity, simple and controllable process, few impurities, reduction of acid and alkaline emission and environmental friendliness are realized, industrialization can be realized beneficially, and the method has a promising application prospect in the pharmaceutical field.

The invention relates to 7alpha-oxhydryl sterol dehydrogenase and an encoding gene and application thereof, and belongs to the technical field of biology. The 7alpha-oxhydryl sterol dehydrogenase is protein shown in SEQ ID NO.1 or protein with the same functions, obtained through substitution and/or deletion and/or addition of one or more amino acid residues of an amino acid sequence shown in theSEQ ID NO.1. The 7alpha-oxhydryl sterol dehydrogenase can catalyze an asymmetric reduction reaction of carbanyl groups of C7alpha-oxhydryl groups of taurocholic acid, glycocholic acid, taurochenodeoxycholic acid and glycochenodeoxycholic acid and catalyze an asymmetric reduction reaction of carbanyl groups and oxhydryl groups in benzoyl groups of ethyl benzoylformate. Compared with 7alpha-oxhydrylsterol dehydrogenase in clostridium sardiniense, the 7alpha-oxhydryl sterol dehydrogenase has higher catalytic activity and thermostability, and has very high industrial application value.

The invention relates to novel application of taurochenodeoxycholic, and particularly relates to novel application of the taurochenodeoxycholic acid in treating adverse reactions of glucocorticoid medicaments. Through studying on the taurochenodeoxycholic acid, the inventor discovers that the taurochenodeoxycholic acid can resist apoptosis of suprarenal gland cells and promote multiplication of adrenal cortex stem cells so as to recover the hypothalamic-pituitary-adrenal axis inhibition caused by the glucocorticoid medicaments, promotes osteoblast to secrete osteocalcin and improve the reduced bone mineral density so as to recover osteoporosis caused by the glucocorticoid medicaments, and can reinforce the mucosal immunity function and promote multiplication of small intestine stem cells; therefore, the taurochenodeoxycholic acid can be directly administrated or made into various preparations or mixtures for preventing and treating adverse reactions caused by the glucocorticoid medicaments.

The invention discloses a kit for detecting 15 bile acids in serum and an application of the kit, and belongs to the technical field of blood detection. The 15 bile acids comprise a cholic acid, a glycocholic acid, a taurocholic acid, a lithocholic acid, a glycolithocholic acid, a taurolithocholic acid, a deoxycholic acid, a glycodeoxycholic acid, a taurodeoxycholic acid, a chenodeoxycholic acid,a glycochenodeoxycholic acid, a taurochenodeoxycholic acid, an ursodeoxycholic acid, a glycoursodeoxycholic acid and a tauroursodeoxycholic acid. The kit comprises an eluent, a calibration product solution, a mixed internal standard working solution, a protein precipitant and a quality control product. When the kit is used for detecting the bile acids in the serum, a to-be-detected sample does notneed derivatization treatment, pretreatment is simple, a sample dosage is small, sensitivity is high, specificity is strong, more types can be detected, the 15 types of bile acid can be simultaneously detected within 6.5 minutes, and the kit can be used for clinical diagnosis and health assessment of serum bile acids.

The invention relates to the field of biotechnology and medicine, in particular to a method for preparing artificial bear bile powder by biocatalysis of active substances expressed by engineering saccharomyces cerevisiae. The method comprises the following steps: performing liquid culture on saccharomyces cerevisiae which simultaneously expresses 7alpha-hydroxysteroid dehydrogenase (7alpha-HSDH) and 7beta-hydroxysteroid dehydrogenase (7beta-HSDH) genes to prepare a crude enzyme extract; directly converting taurochenodeoxycholic acid in poultry bile products such as chicken gall powder into tauroursodeoxycholic acid with a certain proportion. According to the method, in-vitro double-enzyme catalysis is used, NADP+ is added as an auxiliary factor to promote the reaction, the crude enzyme preparation process is simple, the catalytic reaction condition is mild, the result is stable, the whole process is green, safe, rapid, environment-friendly, pollution-free and controllable, and great significance is achieved by utilizing the biotechnology to replace resources with bear bile powder.

The invention discloses a novel method for detecting a taurocholic acid content and related substances. The method comprises the following steps: taking a taurocholic acid-TRC reference substance as aknown reference substance, dissolving the reference substance by a diluent to form a reference substance solution, and dissolving a taurocholic acid sample by a diluent to form a reference substancesample solution; injecting 20ul of each solution into a liquid chromatograph respectively, recording a peak area, and carrying out calculation according to an external standard method on the basis ofanhydrous taurocholic acid; taking cholic acid as a reference substance, dissolving the reference substance by a mobile phase to form a concentration impurity reference substance solution, and dissolving the taurocholic acid sample by a diluent to form a concentration sample solution; injecting 20ul of each solution into the liquid chromatograph respectively, recording the peak areas of sodium taurocholate and cholic acid in a chromatogram, and calculating the sizes of related substances in the taurocholic acid sample according to the external standard method. Effective separation and accuratequantitative detection of taurochenodeoxycholic acid and chenodeoxycholic acid which are two cholic acid substances with large difference in polarities are realized under the same liquid chromatography condition.

The invention relates to hydroxysteroid dehydrogenase, in particular to a novel 7alpha-hydroxysteroid dehydrogenase gene S1-a-2. A nucleotide sequence of the gene is shown as SEQ ID NO.2. A novel 7alpha-hydroxysteroid dehydrogenase with an amino acid sequence shown as SEQ ID NO.1 is coded and is capable of catalyzing CDCA (chenodeoxycholic acid) and TCDCA (taurochenodeoxycholic acid) to generate 7K-LCA (7-ketone lithocholic acid) and T7K-LCA (tauro-7-keto lithocholic acid), catalytic activity of the novel 7alpha-hydroxysteroid dehydrogenase for the CDCA or TCDCA is about twice of that of Clostridium sardiniense 7alpha-HSDH for the same, and accordingly the novel 7alpha-hydroxysteroid dehydrogenase is high in industrial application value.

The invention discloses a cerebral infarction early diagnosis marker, a screening method and application, and a construction method and application of a cerebral infarction early diagnosis model. The diagnostic marker is composed of 4-dimethylallyltryptophan, taurochenodeoxycholic acid-3-sulfate, tri-hexose ceramide (d18: 1/18: 0), lysophosphatidylcholine (18: 0), arginine-alanine, asparaginic acid-tryptophan, methionine-arginine, sphingomyelin d37: 5, phosphatidyl glycerol (12: 0/21: 0) and glucosylceramide (d18: 0/18: 0). The diagnostic marker is screened out by simultaneously carrying out metabonomics analysis and lipidomics analysis on serum by utilizing a UPLC-MS (Ultra Performance Liquid Chromatography-Mass Spectrometry) technology; the sensitivity, the specificity, the accuracy and the AUC of the method for constructing the diagnosis model by utilizing the diagnosis marker are all greater than 0.9, and the method can be used for accurately distinguishing cerebral infarction patients from healthy people and can be used for early diagnosis of cerebral infarction.